Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

What is the RELIANCE Study?

This study is designed to compare azithromycin and roflumilast to prevent COPD flare-ups and hospitalizations. Both azithromycin and roflumilast are FDA approved drugs, and have been shown to reduce the risk of flare-ups, but it is unclear which treatment works better compared to the other.

RELIANCE1
REL
You might qualify for this if you have:
  • COPD with flare-ups and symptoms despite being on standard inhaler therapy
  • A hospitalization for COPD in the last 1 year
  • At least a 10-pack year smoking history

What Will My Role Be in the Study?

The trial works with your doctor to randomize you to receive a prescription for either azithromycin or roflumilast. This is like a coin-flip, your doctor does not choose which medicine you are prescribed. You will be in the study for at least 6 months, and up to 3 years. No research visits are required, and the data will be obtained by review of your records. Your doctors will continue to provide your care, and you will receive phone calls from the study team every 3-6 moths.

You will be compensated for your time.

image-asset
Interested in a Research Study, Click Here For Our Registry Survey!
© 2024 Emphysema COPD Research Center

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!